Aida Pharmaceuticals, Inc. (AIDA)

Market Cap	8.13K -98.5%
Revenue (ttm)	40.51M +41.3%
Net Income	-2.18M
EPS	-0.08
Shares Out	27.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	11,293
Open	0.0003
Previous Close	0.0002
Day's Range	0.0003 - 0.0003
52-Week Range	0.0002 - 0.0003
Beta	24.10
RSI	42.05
Earnings Date	n/a

About Aida Pharmaceuticals

Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 450
• Stock Exchange: OTCMKTS
• Ticker Symbol: AIDA

Financial Performance

In 2007, Aida Pharmaceuticals's revenue was $29.20 million, a decrease of -1.48% compared to the previous year's $29.64 million. Earnings were $2.74 million, an increase of 88.49%.